




ophthalmology
futures forums
European Forum
Virtual 2020

Thursday 01 October

Forum Programme





Imagine Your Happiness

Vision, a window to the world.
With vision, we connect with others.
With vision, we feel happiness.

That is why we at Santen believe
seeing is integral to life.

As a company focused on vision,
we explore and grow the unlimited potential
of our ability to see.

Because we know we can one day
achieve a world free of vision problems.

Because we know we can one day
create a future full of smiles
where everyone's vision is nurtured.

Until then, we will not stop challenging ourselves.



Imagine Your Happiness

Welcome

Timings

Speakers

Presenting companies | Pannelists | Chairs

Our sponsors

Platinum

Gold

Silver

Bronze

New innovator

Exhibitor

Save the date 2021

Programme committee

3

4

5

6

7

8


9

12

13

14

15



Welcome: European Virtual Forum

Dear colleagues,

Welcome to Ophthalmology Futures (OF) European Forum 2020. While we will miss getting together in Amsterdam, the virtual format allows for opportunities to reach a wider audience and hear from speakers who otherwise would not have been able to attend each forum has a unique theme while maintaining our commitment to bringing together all stakeholders in the advancement of eye care. Our format involves showcasing companies at various stages of the innovation process and we are delighted that our combined Retina and European Forums this year will present a record 45 companies.

Topics for panel sessions will address the latest trends and controversies in cataract surgery, hot topics in glaucoma and dry eye as well the challenges of practice and business in the COVID-19 era. We will hear from investors as well as regulatory and corporate leaders from throughout the world.


As always, we would like to thank our advisory board, programme committee, corporate presenters, sponsors and eminent faculty for their invaluable support and assistance without which this meeting would not be possible. Our sponsors have made it possible to offer this meeting free of charge to all attendees for which we are particularly grateful.

Thank you for joining us for Ophthalmology Futures European Forum 2020.

Keith Barton and Kuldev Singh
on behalf of the Ophthalmology Futures Team



Vision Futures Limited, London, UK.
Registered in England No: 8125858.



12:30 - 12:40

Welcome from the Co-chairs

Chairs:

- Keith Barton
- Kuldev Singh

12:40 - 12:50

Market Overview

- Mike Giaquinto

12:50 - 13:20

Panel 1: The Global Dry Eye Opportunity: Will it Ever be Realised?

Chairs:

- Christophe Baudouin
- Shigeru Kinoshita

Panellists:

- Mayssa Attar
- Ashley Brissette
- George Ousler
- Karl Stonecipher
- Nikolaos Tripodis

13:20 - 14:20

Company Presentations 1

Aerie Pharmaceuticals | Michelle Senchyna

Photon Therapeutics | Sunil Shah

EyeYon Medical | Nahum Ferera

Avellino | Eric Bernabei

TearClear | Robert Dempsey

Oculus S.A. | Marcia de Souza Lima

Isarna Therapeutics | Marion Munk

14:20 - 14:50

Panel 2: Big idea and No Money: Who Do I Call in a Big Company?

Chairs:

- Leonard Borrmann
- Baldo Sforzolini

Panellists:

- Laurent Attias
- Doug Faunce
- Chuck Hess
- Jane Rady
- Naveed Shams
- Euan Thomson

14:50 - 15:10

Leadership Perspective

- Kuldev Singh
- Shigeo Taniuchi

15:10 - 15:40

Panel 3: Drug Delivery for Eye Diseases: Simply Cool Technology or also a Commercial Success?

Chairs:

- Eugene de Juan
- Ingeborg Stalmans

Panellists:

- Fred Guerard
- Greg Kunst
- Sabri Markabi
- Michael McCleerey
- Mike Robinson

15:40 - 16:10

Panel 4: Cataract and Other Elective Surgery in the Era of COVID-19

Chairs:

- Arthur Cummings
- Matteo Piovella

Panellists:

- Aylin Kiliç
- Richard Lindstrom
- Todd Pinkney
- Karlheinz Rein
- David Spalton

16:10 - 17:10

Company Presentations 2

Implandata Ophthalmic Products | Max Ostermeier

Kali Care | Sina Fateh

NovaSight | Ran Yam

Azalea Vision | Enrique Vega

Intelon Optics | Dimitri Chernyak

2EyesVision | Susana Marcos

17:10 - 17:40

Panel 5: Refractive Outcomes after Cataract Surgery: IOL Adjustment Vs Enhancement

Chairs:

- Gerd Auffarth
- Damien Gatinel

Panellists:

- Ike Ahmed
- Marcus Ang
- Michael Mrochen
- Mikhail Boukny
- Alex Long
- MK Raheja

17:40 - 18:20

Panel 6: Premium IOL Patient-reported Outcomes and Regulatory Processes

Introductory talk and Discussion Panel

Chair:

- Malvina Eydelman

Panellists:

- Jorge Alio
- Ron Hays
- Kendra Hileman
- Flora Lum
- Scott Macrae
- Sam Masket
- Marie-José Tassignon

18:20 - 19:20

Company Presentations 3

Voptica | Pablo Artal

LensGen | Sumit Garg

AcuFocus | Yari Mitchell

Samsara Vision, Inc. | Thomas Ruggia

Sanoculis | Nir Israeli

iStar Medical | Michel Vanbrabant

Rheon Medical | Nikos Stergiopoulos

19:20 - 19:50

Panel 7: Will Endothelial Damage Restrict Glaucoma Device Progression?

Chairs:

- Keith Barton
- Don Budenz

Panellists:

- Ike Ahmed
- Victor Chan
- Greg Kunst
- Chelvin Sng
- Ingeborg Stalmans
- Brett Trauthen
- Vanessa Vera

19:50 - 20:20

Panel 8: Opportunities in Ophthalmology - Investors' Perspective

Chair:

- Nanna Luneborg

Panellists:

- Mike Giaquinto
- Joseph Gilliam
- Wende Hutton
- Michael Keyoung
- Andrew Murray-Lyon
- Katya Smirnyagina

20:20 - 21:10

Company Presentations 4

Sight Sciences | Patrick Smale

Liqid Medical | Daemon McClunan

Belkin Laser | Daria Lemann Blumenthal

Centricity Vision | Rob Thornhill

LENSAR, Inc. | Nick Curtis

21:10 - 21:40

Panel 9: Femto a Decade Later: Was it Worth the Investment?

Chairs:

- David Chang
- Boris Malyugin

Panellists:

- Jorge Alio
- Laurent Attias
- Soon-Phaik Chee
- Sheraz Daya
- Sunil Shah
- Troy Wu

21:40 - 22:10

A View from the Top: The Long-term Impact of COVID-19 on the Business of Ophthalmology

Chair:

- James Mazzo

Panellists:

- Chris Calcaterra
- Jag Dosanjh
- Warren Foust
- Shervin Korangy
- Caren Mason
- Ludwin Monz
- Michael Onuscheck


22:10 - 22:15

Summary and Concluding Remarks from the Co-chairs

Chairs:

- Keith Barton
- Kuldev Singh

End



Chairs & panellists

A

- **Andrew Murray-Lyon** | Director, RBC Capital Markets
- **Arthur Cummings** | Consultant Ophthalmologist, Wellington Eye Clinic, Dublin, Ireland
- **Aylin Kiliç** | Assist Proffesor of Ophthalmology, Medipol University, Istanbul, Turkey

B

- **Baldo Sforzolini** | Senior Vice President, Clinical Development, Allergan
- **Boris Malyugin** | Deputy Director general (R&D, Edu), S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia

C

- **Caren Mason** | President & Chief Executive Officer, Staar Surgical
- **Chelvin Sng** | Consultant, National University Hospital, Singapore
- **Chris Calcatera** | Chief Operating Officer, Glaukos Corporation
- **Christophe Baudouin** | Head of Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, Paris. Head of Department of Ophthalmology, Ambroise Paré University Hospital, Paris
- **Chuck Hess** | VP & General Manager, US Surgical, Bausch + Lomb

D

- **Damien Gatinel** | Head of Anterior Segment and Refractive Surgery, Fondation Opthalmologique Adolphe de Rothschild, Paris, France
- **David Chang** | Physician, Altos Eye Physicians, California, USA
- **David Spalton** | Consultant Ophthalmic Surgeon, St. Thomas' Hospital, London, UK
- **Doug Faunce** | Executive Director, Search and Evaluation-Eye Care, AbbVie

E

- **Euan Thompson** | President, Carl Zeiss Meditec Ophthalmic Devices & Head Of Carl Zeiss Meditec Digital Business Unit
- **Eugene de Juan** | Jean Kelly Stock Distinguished Chair in Ophthalmology, ForSight Labs & University of California, USA

F

- **Flora Lum** | Vice-President, American Academy of Ophthalmology, USA

G

- **George Ousler** | Senior Vice President, Dry Eye, Ora Clinical Inc.
- **Gerd Auffarth** | Professor and Chairman, The Department of Ophthalmology, Ruprecht-Karls University of Heidelberg; Director, IVCRC, The David J Apple International Laboratory of Ocular Pathology, The University-Eye Clinic of Heidelberg, Germany
- **Greg Kunst** | Vice President, Global Marketing, Glaukos Corporation

I

- **Ike Ahmed** | Medical Director, Prism Eye Institute, Toronto, Canada
- **Ingeborg Stalmans** | Head of the Glaucoma Unit, University Hospitals Leuven (UZLeuven), Belgium Director of the Laboratory of Ophthalmology, Catholic University of Leuven (KULeuven), Belgium

J

- **Jag Dosanjh** | Senior Vice President, Allergan
- **James Mazzo** | Advisor, Carl Zeiss Meditec, Inc.
- **Jane Rady** | SVP, Corporate Strategy & Business Development, Glaukos Corporation
- **Jorge Alio** | Professor & Chairman of Ophthalmology, University of Miguel Hernandez of Elche, Spain
- **Joseph Gilliam** | Chief Finance Officer and Senior Vice President, Corporate Development, Glaukos Corporation

K

- **Karl Stonecipher** | Clinical Professor, University of North Carolina, USA
- **Karlheinz Rein** | Head of Business Sector, Carl Zeiss Meditec AG
- **Katya Smirnyagina** | Executive Director, Capricorn Venture Partners
- **Keith Barton** | Consultant, Moorfields Eye Hospital, London, UK
- **Kendra Hileman** | VP. Head of Instrumentation R&D, Alcon
- **Kuldev Singh** | Professor of Ophthalmology and Director, Glaucoma Service, Stanford University, USA

L

- **Laurent Attias** | Senior Vice President, Corporate Development Strategy, BD&L and M&A, Alcon
- **Leonard Borrmann** | Head of External Innovation, Johnson & Johnson Vision
- **Ludvin Monz** | President & Chief Executive Officer, Carl Zeiss Meditec AG

M

- **Malvina Eydelman** | Director, Office of Ophthalmic, Anesthesia, Respiratory, ENT & Dental Devices, Food & Drug Administration, Government
- **Marcus Ang** | Associate Professor, Singapore National Eye Centre, Singapore
- **Marie-José Tassignon** | Professor, University of Antwerp. Medical Director, Antwerp University Hospital, Belgium
- **Michael Keyoung** | Managing Director & Head of North America, CBC Group
- **Michael McCleerey** | Vice President, Global Strategy, Aerie Pharmaceuticals
- **Michael Mrochen** | Chief Executive Officer and Founder, IROC Science AG
- **Michael Onuscheck** | President, Global Business and Innovation, Alcon
- **Mike Giaquinto** | Senior Managing Director, SVB Leerink
- **Mike Robinson** | Vice President, Clinical Development, Allergan
- **Mikhail Boukny** | Head of R&D Surgical Ophthalmology, Carl Zeiss Meditec AG
- **MK Raheja** | Global Head, Ophthalmic Implants R&D, Johnson & Johnson Vision

N

- **Nanna Lüneborg** | Partner, Novo Holdings
- **Naveed Shams** | Chief Scientific Officer & Head of Global R&D, Santen Pharmaceutical Co., Ltd.
- **Nikolaos Tripodis** | Global Business Franchise Head Ophthalmology, Novartis Pharma AG

R

- **Richard Lindstrom** | Founder & Attending Surgeon, Minnesota Eye Consultants, USA
- **Ron Hays** | Professor, UCLA Fielding School of Public Health, Los Angeles, USA

S

- **Sabri Markabi** | Health R&D Consulting
- **Sam Masket** | Advanced Vision Care, Clinical Professor Stein Eye Institute, Geffen School of Medicine UCLA, Los Angeles, USA
- **Scott Macrae** | Director of Refractive Services, University of Rochester Medical Center, New York, USA
- **Sheraz Daya** | Medical Director, Centre for Sight, London, UK
- **Shervin Korangy** | Chief Executive Officer, Beaver-Visitec International (BVI)
- **Shigeo Taniuchi** | President & Chief Executive Officer, Santen Pharmaceutical Co., Ltd.
- **Shigeru Kinoshita** | Professor & Chairman of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
- **Soon-Phaik Chee** | Senior Consultant, Singapore National Eye Centre, Singapore
- **Sunil Shah** | Consultant Ophthalmologist, Midland Eye, Birmingham, UK

T

- **Todd Pinkney** | Vice President, Centricity Vision, Inc.
- **Troy Wu** | Senior Director, Business Development, Johnson & Johnson Vision

V

- **Vanessa Vera** | Consultant for Medical Affairs, Glaucoma, Allergan
- **Victor Chan** | Head of Marketing & Sales, Surgical Device, Santen Inc.

W

- **Warren Foust** | Worldwide President, Surgical Vision, Johnson & Johnson Vision
- **Wende Hutton** | General Partner, Canaan Partners

All speakers for the Retina and European forums can be found on our website.

Retina:
www.ophtalmology-futures.com/forums/retina-virtual-forum-speakers

European:
www.ophtalmology-futures.com/forums/euro-virtual-forum-confirmed-speakers

Presenting Company Speakers

#

2EyesVision
Susana Marcos | Co-founder

A

AcuFocus
Yari Mitchell | Chief Business Development Officer

Aerie Pharmaceuticals
Michelle Senchyna | Vice President

Avellino
Eric Bernabei | Chief Sales & Marketing Officer

Azalea Vision
Enrique Vega | CEO

B

Belkin Laser
Daria Lemann-Blumenthal | CEO

C

Centricity Vision
Rob Thornhill | CEO

E

EyeYon Medical
Nahum Ferera | CEO & CO-founder

I

Implandata Ophthalmic Products
Max Ostermeier | CEO

Intelon Optics
Dimitri Chernyak | CEO

Isarna Therapeutics
Marion Munk | CMO

iStar Medical
Michel Vanbrabant | Vice President

K

Kali Care
Sina Fateh | CEO

L

LENSAR, Inc.
Nick Curtis | CEO

LensGen
Sumit Garg | Scientific Advisor

Liqid Medical
Daemon McClunan | Founder & CEO

N

NovaSight
Ran Yam | CEO

O

Oculus S.A.
Marcia de Souza Lima | CMO

P

Photon Therapeutics
Sunil Shah | Consultant Ophthalmologist

R

Rheon Medical
Nikos Stergiopoulos | CEO

S

Samsara Vision, Inc.
Thomas Ruggia | President & CEO

Sanoculis
Nir Israeli | CEO


Sight Sciences
Patrick Smale | Vice President

T

TearClear
Robert Dempsey | CEO

V

Voptica
Pablo Artal | Professor





Alcon is leading in eye care innovation.

We have a long history of industry firsts.

Thanks to our deep research capabilities and global commercial footprint, we are a trusted partner to many innovative companies.

We have completed approximately 30 development/licensing transactions since 2016.

In 2019, we invested \$584 million in research and development, representing 7.9% of our net sales to third parties.

Also in 2019, we received 21 significant product approvals, launched 22 key products, and had 14 first inmarket launches. We have more than 110 pipeline products under development and over 1,300 associates working in R&D.

Alcon is in a position of considerable strength and has a unique opportunity to grow in the large, attractive and expanding \$25 billion global eye care device market (Surgical: \$10 billion; Vision Care \$15 billion).

For more information, go to www.alcon.com



Thanks to the generosity of our sponsors, there is no fee for company presentations and delegate registration is complimentary for everyone.



As one of the world's leading specialty ophthalmology companies, Santen carries out research, development, marketing, and sale of pharmaceuticals, over-the-counter products, and medical devices.

In Japan, Santen is the market leader for prescription ophthalmic pharmaceuticals and has a strong presence in Asia and Asia Pacific with direct operations established in several countries as well as with distributor partners. Also, it has been active in the European market since 1994 and is enjoying steady growth in EMEA (Europe, Middle East and Africa). Santen has major sites throughout the world and its products are now reaching patients in over 60 countries. With cultivated scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to the society.

This year, Santen has set a new long-term vision, aiming to become a "social innovator". In this vision, we have described WORLD VISION, "Happiness with Vision" which indicates that we will strongly pursue the Happiest Life for every individual, through the Best Vision Experience. In order to achieve this WORLD VISION, we have also formulated Santen 2030, showing what we aspire to be in 2030 and beyond. As there are still many countries and regions in the world where ophthalmic treatments are not sufficiently available and where medical needs are unmet, Santen is truly dedicated with People-Centric mind to achieve our goal to reduce the loss of social and economic opportunities for people around the world due to visual impairments or blindness and to help to realize the people's happiness. At Santen, we devote ourselves not only to develop innovative pharmaceutical technologies but also to accelerate the ecosystem development, raise people's awareness toward better eye condition, and build society that is inclusive regardless of visual impairment.

For more information, go to www.santen.com



Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the industry.

For more information, go to www.allergan.com



STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL," which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries.

To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

For more information, please visit www.staar.com



Seeing beyond

The Medical Technology segment of ZEISS offers complete solutions to diagnose and treat ophthalmic diseases. In the field of microsurgery the company provides innovative visualization solutions.

With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, the company supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations. ZEISS also offers visualization solutions for dental treatment and gynecology. The company's medical technology portfolio is completed by future-oriented technologies such as intraoperative radiotherapy.

Through our global network we are well aware of our customers' demands. Worldwide neurosurgeons, ear, nose and throat specialist and ophthalmologists – if they are clinicians or if they are office-based – put their trust in the know-how of ZEISS. We are playing an active role in the rapidly proceeding digitalization of the medical sector by offering software solutions for simple and effective patient data management.

For more information, go to www.zeiss.com



Apellis is a global biopharmaceutical company that combines courageous science, creativity, and compassion to deliver life-changing medicines. We are exploring the potential of targeting C3, the central protein of the complement system. With four Phase 3 studies in two disease areas underway, Apellis has emerged as the leader in the research of targeted C3 therapies.

We are developing intravitreal pegcetacoplan (APL-2), an investigational targeted C3 therapy that has the potential to be the first approved treatment for geographic atrophy (GA). In July 2020, we announced that Apellis completed enrollment in the Phase 3 DERBY and OAKS studies investigating intravitreal pegcetacoplan in GA secondary to age-related macular degeneration (AMD). We anticipate top-line results from these two pivotal studies, enrolling a total of 1,259 patients, in Q3 2021.

For more information, go to www.apellis.com



Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.

For more information, go to www.novartis.com



Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and launched its next-generation iStent inject® device in the United States in September 2018.

In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease. For more information, go to www.glaukos.com



REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.

For more information, go to www.regenxbio.com



For more information, go to www.aeriepharma.com



With nine decades of delivering high quality solutions and innovation to advance eye surgery, BVI partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. Our Company aspires to be the most trusted and valued partner to our customers worldwide. Our trusted brands include: Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs).

For more information, go to www.bvimedical.com



Avellino is a precision medicine company specializing in genetic data, diagnostics and therapies. Founded in 2008, Avellino continues to advance genetic testing in eye care with the 2019 launch of AvaGen, the first genetic test to detect risk for keratoconus and the presence of corneal dystrophies. In March of 2020, Avellino pivoted all operations in the US to

focus solely on coronavirus testing, creating the ACTS program to help doctors reopen their practices and surgery centers. Avellino has performed nearly 250,000 coronavirus tests across the US. In August, the company reached the 1 million genetic and molecular testing milestone, a testament to the company's expertise, vision and ability to react quickly to the needs of diverse patient populations.

For more information, go to www.avelino.com



Centricity Vision, Inc. is a global ophthalmic technology company focused on providing innovative solutions to help surgeons achieve excellence. The company's ZEPTO® Precision Cataract Surgery platform adds a new level of safety and precision. ZEPTO® is unique in its ability to produce an automated anterior capsulotomy which is intraoperatively centered on the patient's visual axis, optimizing cataract surgery outcomes. A 510k clinical study cleared by the FDA, enrolled 100 patients and was successfully conducted at eight US sites. This study proved safety and efficacy, demonstrating a consistent capsulotomy diameter of 5.2mm with no capsule abnormalities. The company's intellectual property position is strong, with 20 patents issued and 16 more pending. The management team is seasoned with deep experience in medical device development and commercialization. ZEPTO® adds a new level of safety and precision to all cataract surgeries. Over 40,000 cases have been performed worldwide. ZEPTO® has been used successfully in monofocal implant cases, as well as patients demanding precise results from their premium IOL procedures. The recent financing led by DeCheng Capital allows Centricity Vision, Inc. to build on the ZEPTO® platform, leverage our extensive IP portfolio and continue to develop innovative, synergistic products to benefit cataract surgery.

For more information, go to www.zaptozone.com



Graybug Vision is a clinical stage biopharmaceutical company focused on developing transformative medicines to treat chronic diseases of the retina and optic nerve.

The company's proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for up to six months and potentially longer, improving patient compliance, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug's lead product candidate, GB-102, a microparticle depot formulation of sunitinib malate, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration, with a six-month dosing regimen. Graybug is also using its proprietary technologies to develop GB-401, an injectable depot formulation of a beta-adrenergic prodrug, for primary open angle glaucoma, with a dosing regimen of once every six months or longer.

For more information, go to www.graybug.vision.com



LENSAR®, Inc., the leader in next-generation femtosecond cataract laser technology, continues to focus on astigmatism with the latest system upgrade, Streamline® IV. This includes numerous enhancements

unique to the LENSAR Laser that are dedicated to help surgeons confidently manage astigmatism and optimize patient outcomes, for both toric IOLs and arcuate incisions. Enhancements include IntelliAxis Refractive Capsulorhexis®, which incorporates steep axis markings that help guide precise and confident toric IOL alignment, and wireless transfer of preoperative diagnostics from the Cassini® Corneal Shape Analyzer and Pentacam®, for seamless treatment planning. Iris registration further contributes to the system's accuracy by comparing a pre-op image to a scan of the docked eye taken at the laser to automatically account for cyclotorsion. Building on the strength of LENSAR's foundational femtosecond cataract laser platform, the LENSAR Laser with Streamline IV is revolutionizing a surgeon's ability to deliver great outcomes for astigmatic patients.

For more information, go to www.avelino.com



Intelon Optics® is a medical device company focusing on the development and commercialization of their Brillouin Optical Scanner System (BOSS™). Using non-contact point-by-point capture, this revolutionary device

provides new and useful diagnostic data by understanding the structure of ocular tissues extending from the cornea to the posterior part of the globe. BOSS works by using light energy to measure reverberations through a depth of the ocular tissue. BOSS brings a wide range of novel diagnostic and surgical solutions to empower eye care professionals with confident decision-making and control based on biomechanical tissue properties of the eye. The biomechanics, or biomechanical properties, are primary and critical factors directly impacting the functionality of the eye as a refractive system. They affect functional responses of the cornea and the crystalline lens to light and greatly impact vision. The company's commercial focus begins with refractive surgery and extends to other diagnostic and surgical areas in eye care. Intelon's products will bring revolutionary solutions to allow data-driven surgical outcomes, control of treatment results, and a high level of decision-making confidence to clinicians and surgeons based on biomechanical tissue properties relevant to correction of refractive errors. To date, BOSS is the only technology allowing in-vivo, localized measurement of Young's modulus, a direct measure of the stress-strain relationship of ocular tissues influencing the refractive performance of the eye. For more information, go to www.intelon.com



Neurotech Pharmaceuticals, Inc. is a privately-held biotechnology company focused on developing transformative therapies for chronic eye diseases.

Our patented core technology platform, Encapsulated Cell Therapy (ECT), delivers a genetically-engineered ocular implanted device that continuously produces therapeutic proteins to the eye for multiple years. We have implanted safely our device in several hundred patients.

Neurotech is clinically developing therapies for macular telangiectasia type 2 (MacTel) and glaucoma. Our treatment for MacTel has successfully completed a Phase 2 study and is nearing completion of enrolling two Phase 3 studies. For glaucoma we are taking a novel, neuro-protective approach in treating the disease. We are nearing completion of a 54-patient Phase 2 study conducted under an investigator-sponsored trial at Stanford University and Columbia University.

For more information, go to www.neurotechusa.com



Radiance Therapeutics is developing a next-generation beta therapy device for ophthalmic scar prophylaxis.

This therapeutic modality has been validated in 4 randomised controlled trials from preeminent ophthalmic research teams. Applied topically at the time of surgery, beta therapy has been shown to significantly improve glaucoma filtration surgery outcomes. The most recent of these studies reported odds ratios indicating that beta therapy patients were five and a half times more likely to experience lower IOP at the end of one year than patients treated with antimetabolite mitomycin-C.

For more information, go to www.radiancetherapeutics.com



Sight Sciences is a growth-stage medical device company dedicated to the development of intelligently designed and engineered products that address the underlying physiology of ophthalmic diseases. The company's portfolio consists of the OMNI® Surgical System which is a novel, implant-free device which can be used in combination with cataract surgery or as a standalone procedure, as well as the non-surgical TearCare® System which is a device that applies heat to the eyelids to remove blockage, the hallmark of MGD.

For more information, go to www.sightsciences.com



We **campaign to raise awareness** so glaucoma is detected early and can be treated, we **support people to live well with glaucoma** and we fund **sight saving research**



www.glaucoma.uk



Moorfields Eye Charity supports the incredible and pioneering work of Moorfields Eye Hospital and it's research partner, the UCL Institute of Ophthalmology.

This support is making a difference for patients at the hospital and for people with sight problems around the world.

Call: **+44 (0)20 7566 2565**

Email: **eyecharity@moorfields.nhs.uk**

Website: **www.moorfields.nhs.uk/eyecharity**

Registered Charity No.: 1140679



AcuFocus, Inc., is a privately held ophthalmic medical device company that develops and markets breakthrough technologies for the improvement of vision. Our proven, proprietary technology platform uses a small aperture – or pinhole – effect to allow focused light rays to reach the retina and bring objects into focus. The result is unique, reliable and long-term. Designed specifically for patients with cataracts, the IC-8® IOL combines small aperture optics with the reliability of a monofocal IOL to provide an uninterrupted extended depth of focus. The lens received its CE mark in 2014 and is available in select markets across Europe and Asia. The IC-8 IOL is not currently approved in the United States. Founded in 2001, AcuFocus is based in Irvine, Calif. For additional information about the IC-8 intraocular lens, visit www.acufocus.com



GenSight Biologics is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company recently submitted the Marketing Authorisation Application for its lead product LUMEVOQ®, a gene therapy for treating Leber Hereditary Optic Neuropathy caused by a mutated ND4 mitochondrial gene, in Europe and expects to have top-line results from its pivotal trial for the US available in early 2021. Its second product GS030, which applies optogenetics to treat retinitis pigmentosa, is in Phase I/II trials.

For more information, go to www.gensight-biologics.com



Beyeonics Surgical Ltd is a medical technology company developing surgeon-centered visualization solutions. The company leverages cutting-edge imaging and head-mounted display (HMD) technologies originally developed for aerospace applications. Beyeonics One™ is a new visualization system designed to optimize both anterior and posterior segment surgery integrating advanced technology in the form of enhanced visualization and customized stream of information into the surgical workflow. The platform serves as a digital extension of the surgeon, providing augmented reality visualization that replaces surgical microscopes, while enabling integration of unlimited amounts of data.

For more information, go to www.beyonics.com



iSTAR Medical pioneers minimally invasive, ophthalmic implants for powerful, safe and enduring treatment of patients with glaucoma. iSTAR Medical's flagship product is MINject™, a supraciliary MIGS device made from STAR® material. The innovative STAR material is soft and flexible, medical-grade silicone with a micro-porous, multi-channel geometry which enables bio-integration with surrounding tissues. MINject showed exceptional 2-year results in the STAR-I standalone trial: >40% reduction in IOP to a mean of 13.8mmHg (23.2mmHg at baseline), with around half of patients medication free. Recently published 6-month results of the STAR-II European trial have shown consistent results (Journal of Glaucoma).

For more information, go to www.istarmed.com



Eyevensys is a private clinical stage biotechnology company that is developing a novel approach for treating ocular diseases.

Our mission is to address critical unmet ophthalmic needs using our first-in-class non-viral gene therapy sustained delivery platform to overcome the limitations of current treatment options—including intravitreal injections, surgery, intravitreal implants and biodegradable formulations.

For more information, go to www.eyevensys.com



LensGen®, a clinical stage ophthalmic medical device company headquartered in Irvine, California has developed a disruptive fluid-optic intraocular lens (IOL) for treating cataracts and presbyopia. With its innovative Juvene® IOL the company aims to bring to market this revolutionary device designed to restore full range of vision with quality optics and improved safety due to the modular, capsule filling design. The company is currently progressing through the IDE approval process and is planning a large Series B Financing in early 2021 that will fund the company through approval of the Juvene IOL pivotal FDA study.

For more information, go to www.lensgen.com



Oculis is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies. The Company's leading clinical candidates include OCS-01 and OCS-02.

OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone using Oculis' proprietary Solubilizing Nanoparticle (SNP) technology. It has successfully completed two Phase 2 clinical trials: in Diabetic Macular Edema and for treating inflammation and pain following cataract surgery.

OCS-02 is a novel topical anti-TNF alpha antibody and was in-licensed from Novartis. It has successfully completed two Phase 2 clinical trials in Acute Anterior Uveitis and in Dry Eye Disease.

For more information, go to www.oculis.com

Exhibitor



Ora is the world's leading full-service ophthalmic research organization with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have helped our clients earn more than 45 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's unique models, methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts to maximize the value of new product initiatives.

For more information, go to www.oraclinical.com




Seeing beyond

Join us for the virtual experience and learn more about the latest technologies in eyecare. We have an exciting program lined up, including the unveiling of our all-new virtual showroom!

Register here:

www.zeiss.com/escrs-euretina-registration

ZEISS Ophthalmic Virtual Experience **ESCRS-EURETINA Spotlight 2020** **October 1 – 4, 2020**





ophthalmology
futures forums

Virtual2021

Save
the
Dates
2021

Asian Virtual Forums

Ophthalmology Futures Asian Retina Forum

Virtual 2021 - Thurs. 25 March

Ophthalmology Futures Asian Forum

Virtual 2021 - Fri. 26 March

(Forums begin @ 8am Singapore time)



Ike Ahmed | Division Head, Ophthalmology, Trilium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

Jorge Alio | Professor and Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Vissum Corporation, Spain.

Gerd Auffarth | Professor and Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

Francesco Bandello | Full Professor and Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

David Chang | Altos Eye Physicians and Clinical Professor, University of California, San Francisco, USA.

Steve Charles | Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

Paul Chew | Professor of Ophthalmology, National University of Singapore, Singapore.

Beatrice Cochener | Professor, Chairman, Ophthalmology Department, University Hospital, Brest, France. Past-president, European Society of Cataract and Refractive Surgeons.

Jost Jonas | Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

Sir Peng Khaw | Professor of Glaucoma and Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK.

Shigeru Kinoshita | Professor and Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

Richard Lindstrom | Founder and Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

Boris Malyugin | Chief of Department of Cataract and Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Moscow, Russia.

Prof David Spalton | Past-president, European Society of Cataract and Refractive Surgeons London, UK.

Prof Dr Ingeborg Stalmans | Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head of the Ophthalmology Research Group, University KU Leuven, Belgium.

Paulo Eduardo Stanga | London Vision Clinic Retina Lead Consultant Ophthalmologist & Vitreoretinal Surgeon. Professor of Ophthalmology & Retinal Regeneration, University of Manchester, UK.

Paul Rosen | Consultant Ophthalmic Surgeon, Oxford Eye Hospital, Oxford, UK.

José-Alain Sahel | Endowed Professor and Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital and Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

Chelvin Sng | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

Julian D. Stevens | Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

Donald Tan Tiang Hwee | Arthur Lim Professor at the SNEC and Duke-NUS Medical School, Singapore. Partner and Senior Consultant Ophthalmic Surgeon at Eye & Retina Surgeons (ERS), Camden Medical Centre, Singapore.

Marie-Jose Tassignon | Past Chief and Chair Department of Ophthalmology Antwerp University and University Hospital Antwerp, Belgium.

Adnan Tufail | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

Tien Yin Wong | Vice Dean, Academic & Clinical Development, Duke-NUS Medical School, Singapore. Provost's Chair Professor, National University of Singapore. Deputy Group Chief Executive Officer (Research and Education), SingHealth, Singapore. Medical Director & Senior Consultant Ophthalmologist, Singapore National Eye Centre. Chair, Ophthalmology and Visual Sciences Academic Clinical Programme. Chairman, Board of Directors, Singapore Eye Research Institute, Singapore.

Advisors

Laurent Attias | Senior Vice President, Head of Strategy, BD&L and Market Access, Alcon, USA.

Leonard Borrmann | Divisional Vice President Research and Development, Abbott, USA.

Eugene de Juan | Jean Kelly Stock Distinguished Chair in Ophthalmology, ForSight Labs and University of California, Menlo Park, California.

Tom Dunlap | Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

Malvina Eydelman | Director, Division of Ophthalmic and Ear, Nose and Throat Devices ODE/CDRH/FDA, USA.

Akira Kurokawa | JChief Executive Officer and President Santen Pharmaceutical Co.

James Mazzo | JGlobal President Ophthalmic Devices, Carl Zeiss Meditec, USA.

Calvin Roberts | Senior Vice President and Chief Medical Officer, Bausch+Lomb, USA.

Brent Saunders | Chief Executive Officer and President, Allergan, USA.

Baldo Sforzolini | Senior Vice President of Clinical Development, Allergan, USA.

Naveed Shams | President and Chief Executive Officer, Santen Inc., USA.

Naveed Siddiqi | Novo Ventures.

John Wilkinson | Director of Devices, Medicines and Healthcare Products Regulatory Agency, UK.

Organising Committee

Keith Barton | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK.

Don Budenz | Professor and Chairman, Department of Ophthalmology, University of North Carolina, USA.

Kuldev Singh | Professor of Ophthalmology and Director of Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

Lea Pietrolongo | Operational Director, Ophthalmology Futures Forums, UK.

GLAUKOS.

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

Our unwavering focus sets us apart in the global ophthalmic marketplace and allows us to dedicate the full strength of our resources, talents, and energy towards enriching the lives of and providing treatments for ophthalmic patients.

glaukos.com

NYSE: GKOS

©2020 Glaukos Corporation. Glaukos is a registered trademark of Glaukos Corporation. PM-US-0208

PROUD
SPONSORS

GLAUKOS®



REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.

For more information, please visit www.regenxbio.com

Apellis

Apellis is a global biopharmaceutical company that combines courageous science, creativity, and compassion to deliver life-changing medicines. We are exploring the potential of targeting C3, the central protein of the complement system. With four Phase 3 studies in two disease areas underway, Apellis has emerged as the leader in the research of targeted C3 therapies.

We are developing intravitreal pegcetacoplan (APL-2), an investigational targeted C3 therapy that has the potential to be the first approved treatment for geographic atrophy (GA). In July 2020, we announced that Apellis completed enrollment in the Phase 3 DERBY and OAKS studies investigating intravitreal pegcetacoplan in GA secondary to age-related macular degeneration (AMD). We anticipate top-line results from these two pivotal studies, enrolling a total of 1,259 patients, in Q3 2021.

For more information, please visit www.apellis.com



Envisioning the future

 **NOVARTIS** | Reimagining Medicine



Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the industry.

For more information, please visit
www.allergan.com



STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL," which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries.

To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit **www.staar.com**

Alcon

We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products, because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years — and as the new Alcon, it's what guides our focus towards the brilliant future ahead.

Learn more at alcon.com

CONNECT WITH US!



@AlconEyeCare
@AlconCareers



@Alcon

© 2020 Alcon Inc. 09/20 2009A823

